Welcome to issue 39 of Multiple Myeloma Research Review.
This issue’s selection includes research reporting that switching elderly intermediate-fit patients with MM to reduced-dose lenalidomide maintenance without dexamethasone after nine cycles of Rd was both feasible and provided outcomes similar to those associated with continuing Rd.
As usual we have attached the PDF, and now you can also view the issue online.
Other highlights include:
• Isatuximab-carfilzomib-dexamethasone in relapsed MM
• Temporal changes of MM care costs in Denmark and Sweden
• Subcutaneous daratumumab formulation for relapsed/refractory MM
We hope you will enjoy the papers selected for this issue and you find them beneficial to your clinical practice. Please continue sending your feedback and suggestions.
Kind regards,
Dr Ken Romeril: kennethromeril@researchreview.co.nz
Dr Henry Chan: henrychan@researchreview.co.nz